Ranbaxy Southeast Asia Area Director Jeyabalan Thangarajah Says Lipitor Generic Sales In Malaysia Strong: An Interview With PharmAsia News
This article was originally published in PharmAsia News
Executive Summary
Ranbaxy Malaysia Managing Director Jeyabalan Thangarajah, who is also the Area Director for the Association of South East Asian region, sees Asia continuing to be a major catalyst for growth in the global pharmaceutical market, which he says is poised to grow to $1 trillion by 2014. Thangarajah sat down with PharmAsia News' Singapore bureau to discuss his views on the Southeast Asian pharma market and trends in the region, including Ranbaxy's experience in selling generic versions of Pfizer Inc's Lipitor in Malaysia, as well as assimilating with parent company Daiichi Sankyo Co. Ltd.
You may also be interested in...
Ranbaxy Chairman Says No Change To Lipitor Generic Launch Timeline In U.S.; Dismisses Speculation Of $1 Bn FDA Penalty
MUMBAI - Share prices of Ranbaxy Laboratories Ltd. rose nearly 5% on an otherwise flat day of trading at the Bombay Stock Exchange backed by news that the company is "on schedule" to launch generic versions of Lipitor (atorvastatin) in the United States
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).